The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust ...

A much more efficient approach would be testing for multiple causes that have overlapping symptoms with a single test. That’s the promise of syndromic testing — using molecular diagnostic ...

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

A n analysis of Medicare claims data found a 60-fold increase in the use of unregulated rapid molecular diagnostic tests for urinary tract infections (UTIs) in older adults from 2016 to 2023 ...

This integration aims to enhance the efficiency of ordering and delivering molecular tests, allowing healthcare providers to electronically place orders, track them, and receive results within an ...

HealthDay News — A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk U.S. population, according to a study presented at the American ...

(NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital ...

Yuka Manabe and her team at the Center for Innovative Diagnostics for Infectious Diseases aim to improve global health with ...

Abbott also currently offers the FDA-cleared molecular Alinity M STI assay to detect and differentiate between Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma ...

Let’s take a look at this question with respect to molecular tests for detecting tuberculosis (TB) and drug resistance, which can be used for diagnosing many other diseases as well.